Tissue necrosis resulting from critical limb ischemia (CLI) leads to amputation in a significant number of patients. Autologous cell therapy using angiogenic cells such as endothelial progenitor cells (EPCs) holds promise as a treatment for CLI but a limitation of this treatment is that the underlying disease etiology that resulted in CLI may also contribute to dysfunction of the therapeutic EPCs. This study aimed to elucidate the mechanism of EPC dysfunction using diabetes mellitus as a model and to determine whether correction of this defect in dysfunctional EPCs ex vivo would improve the outcome after cell transplantation in the murine hind limb ischemia model. EPC dysfunction was confirmed in a homogenous population of patients with type 1 diabetes mellitus and a microarray study was preformed to identify dysregulated genes. Notably, the secreted proangiogenic protein osteopontin (OPN) was significantly downregulated in diabetic EPCs. Furthermore, OPN-deficient mice showed impaired recovery following hind limb ischemia, suggesting a critical role for OPN in postnatal neovascularization. EPCs isolated from OPN KO mice showed decreased ability to adhere to endothelial cells as well as impaired angiogenic potential. However, this dysfunction was reversed upon exposure to recombinant OPN, suggesting that OPN may act in an autocrine manner on EPCs. Indeed, exposure of OPN knockout (KO) EPCs to OPN was sufficient to induce the secretion of angiogenic proteins (IL-6, TGF-α, and FGF-α). We also demonstrated that vascular regeneration following hind limb ischemia in OPN KO mice was significantly improved upon injection of EPCs preexposed to OPN. We concluded that OPN acts in an autocrine manner on EPCs to induce the secretion of angiogenic proteins, thereby playing a critical role in EPC-mediated neovascularization. Modification of cells by exposure to OPN may improve the efficacy of autologous EPC transplantation via the enhanced secretion of angiogenic proteins.
INTRODUCTION
survival rate of less than 30%. Thus, the need to develop new therapies is imperative to improving both the quality of life and survival rate of patients. Currently, bone Critical limb ischemia (CLI) is the end stage of peripheral vascular disease (PAD) and leads to ischemia, marrow-derived stem and progenitor cells show some promise as a therapeutic for CLI [reviewed in (21) ]. resulting in pain at rest and tissue loss. Improvement of blood flow often requires surgical or endovascular Endothelial progenitor cells (EPCs) show particular promise as a therapeutic agent as numerous studies sup-revascularization. However, in over one third of patients revascularization either fails or is not possible due to port their role in augmenting angiogenesis (14) . However, a potential limitation of autologous EPC therapy is comorbid complications (1) . In these patients major amputation is often necessary and results in a 5-year that the disease state that results in CLI may also 1096 VAUGHAN ET AL.
adversely affect EPC function and thus limit therapeutic angiogenesis assays (23, 31) . Similarly, bone marrowderived mononuclear cells derived from streptozotocin-efficacy. Indeed, in diabetes mellitus, where CLI is a common complication, patients have fewer EPCs than induced diabetic mice yield fewer EPCs and they exhibit dysfunction, as they are less likely to incorporate into healthy volunteers (9, 23, 31) , while patients with type 2 diabetes complicated by peripheral vascular disease newly forming vascular structures in a Matrigel plug assay than those from healthy mice (29). Beyond effects have an even further reduction in the number of EPCs and in these patients EPC number inversely correlates mediated directly by the cells, it has also been noted that conditioned media from T1DM EPCs has a reduced with glycemic control (9).
If a simple reduction in EPC number is the primary capacity to mediate angiogenesis and may actually inhibit angiogenesis in vitro (23) . Taken together, these data sug-issue then autologous cell therapy, where an infusion of cells is delivered directly to the diseased area, should be gest that the use of autologous cells may be limited by the inherent dysfunction of the transplanted cells. There-sufficient to restore normal function. However, the issue is more complex as studies have revealed that EPCs fore, we used EPCs from type 1 diabetic patients as a model for EPC dysfunction with the goal of elucidating from diabetic patients and animals are not only decreased in number but are also dysfunctional. EPCs from techniques to manipulate the EPCs to increase their therapeutic potential in a model of cell transplantation. patients with type 2 diabetes mellitus (T2DM) exhibit decreased adhesion to activated endothelial cells and to
We used microarray analysis to identify genes that are dysregulated in diabetic EPCs and determine if these matrix molecules including collagen and fibronectin, and EPCs derived from patients with both T1DM and genes contribute to EPC-mediated angiogenesis. The expression of osteopontin (OPN) was found to be T2DM are impaired in their ability to form tubules in decreased in diabetic EPCs. OPN is a secreted glycopro-ischemia is impaired in OPN knockout (KO) mice and we went on to demonstrate that EPCs from OPN knock-tein that is involved in cell migration, cell survival, regulation of immune cell function, inhibition of calcifi-out mice are dysfunctional. We found that OPN may act on EPCs in an autocrine manner, resulting in the secre-cation, and control of tumor cell phenotype (5, 10, 11, 32) . Interestingly, OPN has been implicated in the process of tion of additional angiogenic factors. Furthermore, in a murine model of hind limb ischemia in the OPN knock-neovascularization in various cancer models and peripheral ischemia (10,11). OPN overexpression is associated out mouse, a model of EPC dysfunction, injection of OPN KO EPCs preincubated with OPN resulted in with the increased invasiveness of cancers while inhibition of OPN suppresses tumorigenicity (12, 25, 27, 30, 35) .
improved blood flow to the injured limb. These data indicate that OPN is a potential target for the regulation Studies in noncancerous animal models also support a role for OPN in neovascularization (7, 8) .
of the EPC-mediated angiogenic response to ischemic vascular injury and suggest a novel method to enhance Despite these studies, the precise role of OPN in vessel formation is poorly understood. Further, the relation-therapeutic efficacy of autologous EPC transplantation in peripheral vascular disease. ship between OPN and EPC function is currently unknown. Therefore, we sought to elucidate the underly-MATERIALS AND METHODS ing cause of EPC dysfunction in patients with type 1 Subject Recruitment diabetes mellitus, a model for EPC dysfunction, and assess the putative role of OPN in ischemia and neovas-Patients with poorly controlled type 1 diabetes (as defined by HbA 1/c > 10%) who were on insulin for more cularization. We found that recovery from hind limb the gene expression pattern of genes with a greater than twofold difference in EPCs from healthy controls (n = 4) and EPCs from type 1 diabetes mellitus (T1DM). Three hundred and sixty genes were upregulated in T1DM and 15 were downregulated. OPN was identified as having a 9.6-fold decrease in T1DM EPCs. (B) To test if OPN will restore function to diabetic EPCs, EPCs from both healthy and diabetic subjects were exposed to recombinant OPN. Exposure to OPN was able to significantly restore tubule formation mediated by EPCs in both human and in New Zealand white rabbits (C) (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001.
than 1 year and not on any other medications were peripheral blood mononuclear cells (PBMNCs) were isolated by Ficollpaque (GE Healthcare) density centrif-recruited from the Diabetes Day Centre, University College Hospital Galway, Ireland. Patients with micro-or ugation. After purification with three washing steps, 10 × 10 6 or 2 × 10 6 cells (for cell quantification) were plated macrovascular complications were excluded from the study. Microvascular complications were defined as the on fibronectin-coated six-well plates or four-well glass slides, respectively. Cells were incubated for 4 days at presence of microalbuminuria, diabetic retinopathy, and neuropathy. Macrovascular complications were defined which point the supernatant was discarded, cells were washed with PBS, and fresh endothelial basal media as the presence of any previous history of acute coronary syndrome, peripheral vascular disease, and cerebrovas-(EBM2) was added and changed daily until day 7, when EPCs were used. cular disease. All subjects gave informed consent and were recruited with ethical approval from University College Hospital Galway Clinical Research Ethics Com-Adhesion to Endothelial Cells mittee and the investigation conforms to the principles Adhesion to endothelial cells was determined accordoutlined in the Declaration of Helsinki.
ing to previously described techniques (16). In brief, a Isolation of EPCs monolayer of human umbilical vein endothelial cells (HUVECs; Lonza) was prepared 48 h before the assay EPCs were isolated according to previously described techniques with some modifications (16). Briefly, by plating 2 × 10 5 cells (passage 5 to 10) in each well Operating Software (GCOS). The data sets were normalized by per-chip, per-gene normalization method using GeneSpring bioinformatics software (GeneSpring GX 7.3.1, Silicon Genetics, Redwood City, CA). Gene filterof a four-well glass slide. Twelve hours before the assay ing on normalized intensity followed by one-way the HUVECs in some experiments were treated with ANOVA, multiple testing correction, Benjamini and tumor necrosis factor-α (TNF-α; BD Biosciences) 1 ng/ Hochberg false discovery rate, and Tukey's post hoc ml or media. After the 12 h, 1 × 10 5 EPCs labeled with testing based on values of p < 0.05 and fold changes 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine >2.0-fold was performed to generate list of gene expresiodide (DiI) were added to the HUVECs and incubated sion profile. for 3 h. Nonattached cells were then gently removed with PBS and adherent cells were fixed with 4% para-Primer Sequences formaldehyde (PFA) and counted by a blinded observer.
Primers for OPN (CAGAGCACAGCATCGTCGG; GGCAAAAGCAAATCACTGCAA) and the house-Matrigel Tubule Assay
The assay was performed according to previously described techniques (16). Matrigel (BD Biosciences) included for this study. Phlebotomy was performed via keeping gene, cyclophilin A (TGCTGGACCCAACA to confirm the PCR results. Each sample was analyzed in triplicate. CAAATG; CATGCCTTCTTTCACTTTGCC) (Sigma Genosys) were designed using PrimerExpress software.
Isolation and Identification of Murine Endothelial Progenitor Cells Real-Time PCR
The ABI Prism 7000 Sequence Detection System The hind limbs were separated from the body and the epiphyses were removed from both ends. The marrow (Applied Biosystems) with One Step QuantiTect SYBR Green PCR kit (Qiagen) was used for all PCR experi-was flushed from the bone in 5 ml of endothelial growth medium 2 (EGM-2) and the media with bone marrow ments. The reactions were performed according to the manufacturer's instructions with minor modifications. A was collected and centrifuged at 1,700 rpm for 25 min. The supernatant was removed and cells were resus-sample volume of 25 µl was incubated for 30 min at 50°C; 95°C for 15 min; followed by 40 cycles of 15 s pended in 1 ml of red cell lysis buffer (Sigma). Cells were collected at 1,700 rpm for 5 min and washed twice at 95°C and 30 s at 60°C. The dissociation curves were generated using a temperature range between 60°C and in PBS. Cells were resuspended in 4 ml of EBM2 and plated on a fibronectin-coated plate. EPCs were identified 95°C. All reactions were further analyzed by electrophoresis on 2% agarose gels stained with SyBrGreen dye by direct fluorescent staining to detect fluorescein iso-thiocyanate (FITC)-Ulex europaeus agglutinin-1 lectin nal control within each mouse. Animals were anesthetized with ketamine and xylazine and maintained with (Sigma) and DiI-acetylated low density lipoprotein (acLDL) (Invitrogen) as previously described (13) .
isoflurane. In the second set of experiments, injection of 1 × 10 6 EPCs resuspended in 200 µl of EBM2 (with no supplements added) was performed. There were six Murine Hind Limb Ischemia Model injections into the thigh muscle at the time of surgery. C57BL/6 (strain code 027) (wild-type; WT) and
Laser Doppler Blood Flow Assessment (LDBF) [B6.12956(Cg)-spp1tm1Blh/J] mice were purchased Animals were anaesthetized and placed on a heating from Charles River Lab and Jackson Laboratory, respectable at 37°C before scanning to minimize temperature tively. OPN KO and WT mice aged between 8 and 10 variation. The blood flow in the foot pads of both limbs weeks of age were used. The mice were housed at the was measured using a laser Doppler blood flow analyzer animal facility in the Regenerative Medicine Institute (PeriScan PIMII, Perimed Inc.) immediately before and (REMEDI), NCBES, NUIG. All procedures were after surgery as well as on postoperative days 7, 14, and approved by the Minister of Health and Children under 28. Microvasulature blood flow was displayed in a the Cruelty to Animals Act, 1876. Unilateral hind limb color-coded image. Analysis was performed by comparischemia was created in WT and OPN KO mice as preing blood flow in the ischemic limb (left) to the nonisviously described (19) . In brief, the left femoral artery chemic limb (right) to further minimize variations due and its associated branches were isolated, ligated, and to ambient light and temperature. excised. The contralateral hind limb served as an inter- Three proteins that had decreased expression in OPN KO cells were identified and expression of all three protein expression levels was returned to WT levels upon exposure to OPN, suggesting OPN may induce the secretion of angiogenic factors (n = = 3). *p < 0.05. FGF, fibroblast growth factor; IL-6, interleukin-6; TGF-α, transforming growth factor-α.
Collection of Conditioned Media
background values were subtracted. All data were normalized to the positive control spots to control for differ-EPCs were grown as described until day 6. On the ences between arrays. 6th day of culture the media was removed and cells were washed three times in PBS. One milliliter of fresh Statistical Analysis EBM2 was then added to each well of a six-well plate Data are presented as mean ± SEM. Statistical analyand the plates were then incubated for 24 h at which sis was performed by unpaired Student's t-test for compoint the media was collected for use in the Matrigel parisons between two groups and by one-way analysis tubule assay. Conditioned media for the angiogenesis of variance followed by Bonferroni correction for comarray was obtained by incubating day 6 EPCs in growth parison between more than two groups. A value of p < factor-free EBM2 for 48 h. 0.05 was considered significant. Angiogenesis Array RESULTS Conditioned media (100 µl) was hybridized to each EPC Dysfunction in Type 1 Diabetes Mellitus membrane of an antibody-sandwich angiogenesis array (Panomics) according to manufacturer's guidelines.
We first sought to determine if EPC number and function were impaired in a homogenous population of Expression intensities were determined with Image J and patients with T1DM that did not have micro-or macro-OPN in EPC Dysfunction in DM vascular complications. EPCs were isolated from four patients with T1DM with a mean HbA 1/c of 12.5 ± 4.3%
Having identified diabetes as a model for EPC dysfunction, we sought to elucidate the underlying cause of and a mean duration of diabetes of 7 ± 2.3 years, and four gender-and age-matched (22.3 ± 4.3 vs. 22.8 ± 2.1 this dysfunction. Therefore, a microarray was performed on EPCs obtained from diabetic and control subjects and years old) healthy volunteers were recruited (Fig. 1) . EPCs from patients with T1DM were reduced in both the top 10 genes up-and downregulated are shown (Fig.  3A, Tables 1 and 2 ). Three hundred and sixty genes number and function when compared to EPCs from healthy volunteers (Fig. 2) .
were found to be upregulated in T1DM EPCs and 15 genes downregulated twofold or greater. OPN was need to be physically present to enhance angiogenesis or if they are secreting factors that act in a paracrine found to be markedly reduced in diabetic EPCs and this was confirmed by qRT PCR where OPN was downregu-manner to enhance angiogenesis. lated 26.89-fold in diabetic EPCs.
To further address the potential importance of OPN EPCs Enhance Angiogenesis in a Paracrine Manner in EPC-mediated angiogenesis, diabetic and healthy
To determine if EPCs function to enhance angiogen-EPCs were incubated with OPN and a Matrigel tubule esis in a paracrine manner, conditioned media (CM) assay was performed. Impairment in tubule formation from WT and OPN KO EPCs was obtained and incufrom diabetic EPCs (compared to nondiabetic EPCs) bated with HUVECs in the Matrigel tubule assay. CM was reversed upon exposure to recombinant OPN. Furfrom WT but not OPN KO EPCs induced a significant thermore, this finding was also confirmed with EPCs angiogenic response (Fig. 6C ). To determine if OPN from an alloxan-induced diabetic rabbit model: tubule was responsible for this paracrine effect CM was colformation was restored to nondiabetic levels after expolected from WT cells and incubated with an OPN neusure to recombinant OPN protein (Fig. 3C) .
tralizing antibody. If OPN induces tubule formation, its neutralization in the CM should abrogate the angiogenic Role of OPN in Angiogenesis response. Surprisingly, incubation with the OPN neutral-Having observed that EPCs from patients with T1DM izing antibody did not significantly decrease tubule forwere dysfunctional and expressing decreased levels of mation ( Fig. 6C ), suggesting that OPN does not enhance OPN, we went on to explore the role of OPN in angioangiogenesis directly. Thus, we went on to explore other genesis and vascular wound healing. Hind limb ischemia possible roles OPN could play in mediating angiogenesis. was induced in OPN KO mice and laser Doppler blood flow analysis was performed. Postoperative results in OPN Acts on EPCs in an Autocrine Manner the ischemic limb demonstrate that blood flow was to Enhance Angiogenesis restricted to about 15% of the flow in the control limb in both WT and KO animals. By day 28 blood flow in An alternate mechanism for OPN-mediated angiogenesis is via an autocrine effect on EPCs to secrete the ischemic footpad of WT mice was restored to levels found in the control limb; however, blood flow was angiogenic factors. Thus, incubation with exogenous OPN should be sufficient to elicit the secretion of pro-restored to only about 23% of WT levels in the KO animals ( Fig. 4A, B ). In addition to decreased blood teins that enhance the angiogenic response. Indeed, we found that incubating EPCs with recombinant OPN was flow, we also found that microvascular density was decreased in the ischemic limbs of OPN KO mice when sufficient to enhance tubule formation to levels obtained from WT cells (Fig. 6B ). In fact, incubation with recom-compared to the ischemic limb of WT mice (Fig. 4) .
binant OPN-induced KO cell adhesion to activated Role of OPN in EPC Function endothelial cells to levels surpassing WT cells (Fig. 6A ). Furthermore, if KO cells are incubated with OPN for 24 We next sought to determine if there was a direct link between the impaired angiogenesis observed in KO mice h, followed by removal of the OPN-containing media, and fresh media (without OPN) is added and collected and EPC function. We first determined the ability of WT and KO EPCs to adhere to activated endothelial cells. after 24 h this media is still able to enhance angiogenesis, supporting the possibility that OPN is inducing the EPCs were obtained from the bone marrow of the mice and dual staining of DiI-acetylated LDL and FITC-lectin secretion of angiogenic proteins from EPCs (Fig. 6C) .
To further address this, a chemiarray was used to deter-were confirmed (Fig. 5 ). EPCs from OPN KO mice displayed impaired adherence when compared to WT EPCs mine if there was differential secretion between WT EPCs, KO EPCs, and KO EPCs exposed to OPN. The (Fig. 6A ). Furthermore, when OPN KO EPCs were compared to WT EPCs in a Matrigel tubule assay we secretion of three angiogenic proteins, fibroblast growth factor-α (FGF-α), interleukin 6 (IL-6), and transforming observed that WT EPCs induced significantly more tubule formation than KO EPCs (Fig. 6B) . Taken growth factor-α (TGF-α), were found to be downregulated from KO cells when compared to WT (Fig. 6D ). together, these data suggest that OPN KO EPCs are impaired in their ability to adhere to the site of injury as Interestingly, exposure of KO cells to OPN restored the secretion of these proteins to WT levels. Taken together, well as their ability to induce angiogenesis. Interestingly, although the DiI-labeled EPCs did appear to asso-these data suggest that OPN acts in an autocrine manner on EPCs, resulting in the secretion of angiogenic proteins, ciate with the tubules formed in the angiogenesis assay they did not appear to actually incorporate into the which then act to enhance both the ability of the EPCs to adhere to sites of injury and to induce angiogenesis. tubule structures. Thus, we next questioned if the EPCs
Exposure to OPN Enhances the Angiogenic Potential
circulating EPCs was significantly reduced. Furthermore, we demonstrated that these EPCs were impaired of EPCs in OPN KO Mice in both their ability to adhere to activated endothelial Although it appears that exposure to recombinant cells and their ability to induce tubule formation, which OPN induces the secretion of angiogenic proteins and are two critical indicators of angiogenic potential in vivo. enhances angiogenesis, it is unclear if this is sufficient
Having confirmed that EPC dysfunction exists in a to restore the angiogenic potential of EPCs in vivo.
homogenous cohort of T1DM patients, we used micro-Therefore, we induced hind limb ischemia in OPN KO array analysis to identify gene expression differences, mice and intramuscularly injected untreated KO EPCs, which may explain this observation. OPN was one of a OPN-pretreated KO EPCs, or diluent alone (control).
number of genes found to be dysregulated in diabetic EPCs from OPN KO animals that were pretreated for 24
EPCs following microarray analysis and was confirmed h with recombinant OPN improved blood flow comto be downregulated by qRT-PCR. We proceeded to pared to injection of cells that had not been precondiassess the vascular response to hind limb ischemia in tioned or diluent alone ( Fig. 7 ), suggesting that exposure OPN KO mice. Our results were consistent with those to OPN is sufficient to increase the angiogenic potential of Duval et al., who found OPN KO mice demonstrate of OPN-deficient EPCs.
impaired angiogenesis in response to hind limb ischemia (8). Interestingly, many studies have shown that OPN DISCUSSION is upregulated in response to ischemia (4, 18, 20) . These studies suggest a critical role for OPN in the angiogenic Recent clinical trials, such as Transplantation of Progenitor Cells and Regeneration Enhancement in Acute response but the mechanism is poorly understood. As we demonstrated OPN expression is decreased in EPCs Myocardial Infarction (TOPCARE-AMI) and Therapeutic angiogenesis by cell transplantation (TACT), have from diabetes mellitus, a condition with abnormal EPC function, we hypothesized that the mechanism of OPN-suggested that autologous bone marrow-derived progenitor cell transplantation holds promise for the treatment mediated angiogenesis was via an interaction with EPCs. We next studied the potential role of OPN in EPC of acute myocardial infarction (3, 26) and peripheral vascular disease (24) . While these studies demonstrate the dysfunction using cells isolated from OPN KO mice. OPN KO EPCs have a reduced ability to adhere to acti-safety of autologous cell transplantation and potential for therapeutic benefit, the outcome may be compro-vated endothelial cells and to induce angiogenesis. Furthermore, we found that conditioned media was able to mised by disease-induced cellular dysfunction. This highlights the need to understand the mechanism of dys-induce angiogenesis in vitro, which suggests that EPCs are secreting angiogenic factors, and this is supported function associated with each disease state and how this may limit the effectiveness of treatment. Understanding by recent studies where EPC-conditioned media was demonstrated to contain angiogenic proteins and was disease-associated EPC dysfunction may allow reversal prior to transplantation. In the current study we used able to induce an angiogenic response in vivo (6, 15, 17, 33) . Interestingly, neutralization of OPN was not suffi-diabetes mellitus as a model of EPC dysfunction and determined a mechanistic role for OPN. Furthermore, cient to dampen the angiogenic response induced by CM. This implied that OPN was not directly responsible we showed that OPN plays a crucial role in EPC function in general and that the mechanism is via autocrine for the induction of angiogenesis as its presence was not required in the assay itself. However, exposure of EPCs secretion of angiogenic factors from EPCs. We went on to show that preincubation of dysfunctional EPCs (from to OPN during culture was critical to inducing angiogenesis, which suggested OPN may be acting in an auto-OPN KO mouse) with OPN enhanced the therapeutic efficacy after cell transplantation.
crine manner, stimulating EPCs to turn on a "master switch", thereby promoting angiogenesis via the secre-We used T1DM as a model of EPC dysfunction in order to identify factors involved in cell dysfunction.
tion of a variety of angiogenic proteins. Indeed, we found that exposure to OPN was sufficient to restore the Others have established that there are reduced numbers of circulating EPCs in patients with both T1DM and secretion of at least three proangiogenic proteins to levels observed in WT cells. All three angiogenic proteins T2DM (23, 31) . However, patients with microvascular complications were not excluded from these studies and identified, IL-6, FGF-α, and TGF-α, have been implicated in wound healing and angiogenesis (22, 28, 34) . it has been shown that EPC numbers are increased in patients with diabetic retinopathy (2) . Thus, we studied However, OPN has various cleavage and phosphorylation sites and additional studies need to be performed a population of T1DM patients without diabetic retinopathy or other confounding factors and found, in accor-to determine how OPN activates EPCs to release these angiogenic factors. dance with the previous studies, that the number of as a potent angiogenic factor contributing to tumor
